Document download center

Brochures

Olink brochure

Here you can download our brochure, which presents a concise overview of the Olink offering.

๐Ÿ”— Olink – One proteomics platform, endless possibilities (PDF)

Olinkยฎ Focus flyer

Here you can download our flyer presenting the Olinkยฎ Focus offering.

๐Ÿ”— Olinkยฎ Focus: Our custom panel offering (PDF)

Olinkยฎ Flex flyer

Here you can download our flyer presenting the Olinkยฎ Flex offering.

๐Ÿ”— Olinkยฎ Flex: Flexibility without compromise (PDF)

Validation Data documents

Here you can access full validation data information for both current Olinkย panels. Please note that the content of some panels may have been updated over time. The documents below refer to the most recently available version of the panel only. If you need a previous version of one of our validation data documents that refers to an older version of the panel,ย please contact us directly.

Explore 3072

๐Ÿ”— Validation methods and results Updated Jun 19, 2023

๐Ÿ”— Validation data results Updated July 28, 2023

Target 96 Cardiometabolic

Panel uses a 1:2025 dilution of sample. The measuring ranges shown in Figure 3 correspond to the concentrations in the original biological sample, whereas the figures quoted in Table 1 represent the actual concentration of recombinant analyte measurable in the validation assay. A multiplication factor of 2025 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data.

PDF

Target 96 CVD II

PDF

Target 96 CVD III

Note: the CVD III panel uses a 1:100 dilution of sample. The measuring ranges shown in Figure 3 correspond to the concentrations in the original biological sample, whereas the figures quoted in Table 1 represent the actual concentration of recombinant analyte measurable in the validation assay. A multiplication factor of 100 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data.

 

PDF

Target 96 Cell Regulation

PDF

Target 96 Development

Panel uses a 1:100 dilution of sample. The measuring ranges shown in Figure 3 correspond to the concentrations in the original biological sample, whereas the figures quoted in Table 1 represent the actual concentration of recombinant analyte measurable in the validation assay. A multiplication factor of 100 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data.

 

PDF

Target 96 Immune Response

PDF

Target 96 Immuno-Oncology

Note that this version (2.1) applies to the latest panel version with article number 95311

 

PDF

Target 96 Inflammation

Note that this version (3.0) applies to the latest panel version with article number 95302

 

PDF

Target 96 Metabolism

Note: the Metabolism panel uses a 1:10 dilution of sample. The measuring ranges shown in Figure 3 correspond to the concentrations in the original biological sample, whereas the figures quoted in Table 1 represent the actual concentration of recombinant analyte measurable in the validation assay. A multiplication factor of 10 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data.

 

PDF

Target 96 Neuro Exploratory

Note that this version of the document (1.2) applies to the latest version of the panel with article number 95391 (released July 1, 2019)

 

PDF

Target 96 Neurology

PDF

Target 96 Oncology II

PDF

Target 96 Oncology III

PDF

Target 96 Organ Damage

PDF

Target 96 Mouse Exploratory

PDF

Target 48 Cytokine

PDF

Flex

Protein assay lists

Here you can access the complete biomarker assay list for each panel, listing the long name, short name, and UniProt number for each protein. For Olink Explore panels, the approved Gene name, recommended full Protein name, and the UniProt ID is presented. Since an individual protein may have a number of commonly used names or abbreviations, we recommend using the UniProt ID provided to search the UniProt website if there is any uncertainty.

If you want to search for markers in our complete biomarker library, go to our Protein biomarker search page.

Please note that the content of some panels may have been updated over time. The documents below refer to the most recently available version of the panel only. If you need a previous version of one of our Biomarker list documents that refers to an older version of the panel, please contact us directly.

Disclaimer: The number of assays specified for each Olink Panel actually delivered may be lower than specified. Please reach out to your contact person at Olink for further information.

Explore HT complete assay list

Explore 3072 complete assay list

Olink Explore assay names version history

Olink Explore assays are presented with the UniProt ID and approved Gene Names according to theย official UniProt website.ย  At the beginning ofย  each year, the assay nomenclature is updated if needed according to the latest info from UniProt. All updates are presented in the version history document below:

PDF

Target 96 Cardiometabolic

PDF

Target 96 CVD II

PDF

Target 96 CVD III

PDF

Target 96 Oncology II

PDF

Target 96 Oncology III

PDF

Target 96 Development

PDF

Target 96 Immuno-Oncology

PDF

Target 96 Metabolism

PDF

Target 96 Neuro Exploratory

PDF

Target 96 Cell Regulation

PDF

Target 96 Immune Response

PDF

Target 96 Inflammation

PDF

Target 96 Neurology

PDF

Target 96 Organ Damage

PDF

Target 96 Mouse Exploratory

PDF

Target 48 Cytokine

PDF

Target 48 Mouse Cytokine

PDF

White Papers

Here you can find all the white papers that Olink have produced. These articles leverage the wealth of knowledge and experience in our research and development team, presenting you with useful technical and application-related information.

PEA: Exceptional specificity in a high multiplex format

This white paper shows how the accuracy of the Olinkยฎ Proximity Extension Assay (PEA) technology has been validated regarding recognizing the intended target protein. It shows how Olink tests specificity and how Olink’s customers have validated the PEA technology using orthogonal methods.

PDF

Ensuring quality with flexibility- Olinkยฎ Flex validation & verification

This white paper transparently presents some of the results from our verification and validation tests carried out during the development of Olink Flex.ย 

PDF

Itโ€™s all relative โ€“ 4 reasons why biomarker discovery commonly uses relative quantification

Absolute and relative quantification are performed in proteomics to identify and validate protein biomarkers for clinical applications. In this white paper, four reasons why relative quantification remains the prevalent method for biomarker discovery are provided. Moreover, multiplex proteomic platforms from Olinkยฎ that offer both absolute and relative quantification options are described.

PDF

PEA โ€“ a high-multiplex immunoassay technology with qPCR or NGS readout

A short overview of how the unique technology behind Olink’s biomarker panels with NGS or qPCR readout works and how it overcomes the problems normally associated with multiplexed immunoassays.

PDF

Strategies for design of protein biomarker studies

This white paper describes important aspects of study design to consider when planning your future research.

PDF

Pre-analytical variation in protein biomarker research

This paper provides some guidance on what to consider with respect to sample collection and handling when setting up a protein biomarker study.

PDF

Measuring protein biomarkers with Olink โ€” technical comparisons and orthogonal validation

This white paper addresses how data from Olink studies compares to other technologies. We present examples of comparisons ranging from single-plex ELISAs to high multiplex assays and also provide useful tips for comparisons between Olink data and data from other technologies.

PDF

Data normalization and standardization

This paper describes Olink’s built-in QC system, NPX calculation and definition, and the different normalization methods we use.

๐Ÿ”— White paper Data normalization Version 2.1, updated April 8, 2022

Development and validation of customized PEA biomarker panels with clinical utility

This describes how PEA can be applied to the development and validation of lower-plex assays that could help to translate protein signatures from discovery to clinical utility. The article shows a proof-of-concept study to design a custom panel including assays for both high and low abundance proteins, and providing absolute quantification.

PDF

Multiplex analysis of inflammatory proteins: A comparative study across multiple platforms

๐Ÿ”— Multiplex analysis of inflammatory proteins: A comparative study across multiple platforms

This study compared the Olink Target 48 Cytokine head-to-head with two commonly used commercial multiplex proteomics platforms, as well as to Olink Explore 1536.

๐Ÿ”— Appendix (PDF)

Additional comparative data from the study described in the original white paper.

Application examples

Here you will find documents showing examples of data generated using specific Olink panels, or in specific application areas of interest.

The compatibility of nonhuman primate plasma with Olinkยฎ PEA technology

Olink Mouse Exploratory - Pilot Studies

Technical notes

Here you can download our technical notes, which provide information on technical aspects of our panels

Performance of Olinkยฎ Explore 3072 in Brain Tissue Lysates

Performance of Olinkยฎ Explore 3072 in Brain Tissue Lysates
๐Ÿ”—ย Read now

Compatibility of Olinkยฎ Explore with autoantibodies in autoimmune disease

This technical note provides multilayers of evidence, including Luminex correlations, on how the Explore technology is compatible with plasma samples from patients with Systemic Lupus Erythematosus (SLE, autoimmune disease), despite the presence of high autoantibodies titers, including antibodies against double stranded DNA, that are considered as potential interfering factors in analysis.
๐Ÿ”—ย Read now

Concordance and repeatability tests to evaluate lab performance

This technical note presents concordance testing results on Olinkโ€™s platforms (Olinkยฎ Target 48/96 and Olinkยฎ Explore) generated by Sequanta Technologies and an Olinkยฎ Analysis Services lab.
๐Ÿ”—ย Read now

Extending Olink's Mouse Exploratory panel to studies in rats

PDF

Olinkยฎ Explore readout on NovaSeq 6000 SP vs NextSeq 2000/550

NovaSeqโ„ข 6000 SP vs S4 flow cell comparison

PDF

PEA specificity

PDF

NovaSeq 6000 SP vs S1 flow cell comparison

PDF

High consistency between qPCR readout instruments for Olink data

Consistency with excellence: Lot-to-lot monitoring of Olinkยฎ PEA probes

๐Ÿ”— Technical note Lot-to-lot monitoring of Olink PEA probes Version 1.0, July 24, 2021

Manuals & instructions

Below you will find all our technical user documentation, including manuals, short instructions and guidelines.

Olink Explore HT

๐Ÿ”— Olink Explore HT User Manual (PDF) Version 1.1, updated Sep 15, 2023

๐Ÿ”— Olinkยฎ Explore HT Sequencing using NovaSeq 6000 S4 User Manual (PDF) Version 1.0, updated Aug 29, 2023

Olink Explore 384 & 3072

Download the Olinkยฎ Explore Overview User Manual, as well as the user manuals applicable to the Olink Explore Reagent Kit and NGS instrument to be used.

๐Ÿ”— Olink Explore Overview User Manual (PDF) Version 3.1, updated Jun 28, 2023

Olink Explore Reagent Kits

๐Ÿ”— Olink Explore 384 User Manual (PDF) Version 3.1, updated Jun 26, 2023

๐Ÿ”— Olink Explore 4 x 384 User Manual (PDF) Version 3.1, updated Jun 28, 2023

๐Ÿ”— Olinkย Explore 1536 & Expansion User Manual (PDF) Version 3.0, updated May 12, 2023

๐Ÿ”— Olink Explore 3072 User Manual (PDF) Version 3.1, updated Jun 26, 2023

NGS instruments

๐Ÿ”— Olinkย Explore Sequencing using NextSeq 550 User Manual (PDF) Version 1.2, updated Nov 1, 2022

๐Ÿ”— Olink Explore Sequencing using NextSeq 2000 User Manual (PDF) Version 1.1, updated Nov 1, 2022

๐Ÿ”— Olinkย Explore Sequencing using NovaSeq 6000 User Manual (PDF) Version 1.1, updated Nov 1, 2022

Olink Target

Olink Focus

๐Ÿ”— Olink Focus User Manual (PDF) Updated Dec 15, 2022

Olink Signature Q100

๐Ÿ”—ย Olink Signature Q100 Technical Specifications

๐Ÿ”— Olink Signature Q100 Site Requirements Version 1.4, updated Dec 9, 2022

๐Ÿ”— Olink Signature Q100 Installation Procedure (with external shipping lock) Version 1.2, updated Dec 9, 2022

๐Ÿ”— Olink Signature Q100 Installation Procedure (with internal shipping lock) Version 1.1, updated Jan 25, 2022

๐Ÿ”— Olink Signature Q100 User Manual Version 1.2, updated Dec 6, 2022

Olink NPX Explore HT Software

๐Ÿ”— Olink NPX Explore HT User Manual Version 1.0, updated Aug 14, 2023.

๐Ÿ”— Olinkยฎ Explore CLI for Olinkยฎ Explore HT Version 2.0, updated Aug 14, 2023.

๐Ÿ”— Olinkยฎ Explore Preprocessing Version 4.0, updated Aug 14, 2023.

Olink NPX Explore Software

๐Ÿ”— Olink NPX Explore User Manual Version 2.1, updated Jun 9, 2023.

Olink NPX Signature Software

๐Ÿ”—ย Olink NPX Signature for Olink Focus User Manual Version 1.1, updated Feb 15, 2023

๐Ÿ”—ย Olink NPX Signature for Olink Target 48 User Manual Version 1.1, updated Mar 16, 2023

๐Ÿ”—ย Olink NPX Signature for Olink Target 96 User Manual Version 1.0, updated Feb 15, 2023

๐Ÿ”—ย Olink NPX Signature for Olink Flex User Manual Version 1.1, updated Mar 16, 2023

Olinkยฎ Statistical Analysis app


๐Ÿ”— Olink Insights Stat Analysis User Guide (PDF) Version 1.1, updated Dec 22, 2022

Olinkยฎ Analyze

๐Ÿ”— Olink Analyze Cheatsheet
Version 1.0, updated May 04, 2023

Olink MyData Cloud Software

๐Ÿ”— Olink MyData Cloud User Manual (PDF) Version 5.4, updated Jan 23, 2023

Safety Data Sheets (SDS)

Please view our safety information documents relating to the different components of our products.